Takahide Arimoto

The University of Tokyo, Toranomon Hospital

Papers

2

Total Citations

22

H-Index

2

About

Dr. Takahide Arimoto is a leading figure in gynecologic oncology, whose research is fundamentally reshaping the surgical management of early-stage cervical cancer. His work is centered on a critical, patient-focused question: how can we achieve a cure while minimizing the physical burden of treatment? Dr. Arimoto is a principal investigator for the Japan Clinical Oncology Group (JCOG), most notably leading the pivotal JCOG1101 confirmatory trial. This landmark study rigorously evaluated modified radical hysterectomy for patients with small (≤2 cm) Stage IB1 tumors, providing high-level evidence that less invasive surgery can be safe and effective without compromising oncologic outcomes. His comprehensive 2015 review on the minimization of curative surgery (17 citations) has served as a foundational text, articulating the benefits of reducing surgical radicality for a younger patient population. Through his leadership of practice-changing clinical trials and his advocacy for surgical de-escalation, Dr. Arimoto is directly improving the quality of life for women with cervical cancer, establishing a new standard of care that balances curability with reduced morbidity.

Research Focus

Key Achievements

2
H-Index
2
Papers
22
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Minimization of curative surgery for treatment of early cervical cancer: a review
17 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 29
🏛 Institutions: The University of Tokyo, Toranomon Hospital

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago